Cargando…

Adaptive up-regulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells

Melanoma cells driven by mutant B-RAF are highly resistant to chemotherapeutic treatments. Recent Phase 1 results with PLX4032/RG7204/Vemurafenib, which selectively inhibits B-RAF/MEK/ERK1/2 signaling in mutant B-RAF cells, has given encouragement to this struggling field. Nearly all patients in the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Basile, Kevin J., Abel, Ethan V., Aplin, Andrew E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2011
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262107/ https://www.ncbi.nlm.nih.gov/pubmed/21996740 http://dx.doi.org/10.1038/onc.2011.424

Ejemplares similares

Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors
por: Choi, Jaehyuk, et al.
Publicado: (2014)

Differential sensitivity of melanoma cell lines with BRAF(V600E )mutation to the specific Raf inhibitor PLX4032
por: Søndergaard, Jonas N, et al.
Publicado: (2010)

PLX4032 Mediated Melanoma Associated Antigen Potentiation in Patient Derived Primary Melanoma Cells
por: George, Andrea L., et al.
Publicado: (2015)

PLX4032 resistance of patient-derived melanoma cells: crucial role of oxidative metabolism
por: Garbarino, Ombretta, et al.
Publicado: (2023)

Galectin-3 sensitized melanoma cell lines to vemurafenib (PLX4032) induced cell death through prevention of autophagy
por: Bustos, Silvina Odete, et al.
Publicado: (2018)

ZAK Inhibitor PLX4720 Promotes Extrusion of Transformed Cells via Cell Competition
por: Maruyama, Takeshi, et al.
Publicado: (2020)

Vitamin C sensitizes BRAF(V600E) thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032
por: Su, Xi, et al.
Publicado: (2021)

Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations
por: Niehr, Franziska, et al.
Publicado: (2011)

The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells
por: Jenkins, Molly H., et al.
Publicado: (2015)

HO-1 Limits the Efficacy of Vemurafenib/PLX4032 in BRAF(V600E) Mutated Melanoma Cells Adapted to Physiological Normoxia or Hypoxia
por: Furfaro, Anna Lisa, et al.
Publicado: (2022)

Induced cross-resistance of BRAF(V600E) melanoma cells to standard chemotherapeutic dacarbazine after chronic PLX4032 treatment
por: Erdmann, Sarah, et al.
Publicado: (2019)

Association between acquired resistance to PLX4032 (vemurafenib) and ATP-binding cassette transporter expression
por: Michaelis, Martin, et al.
Publicado: (2014)

Application of in vivo imaging techniques to monitor therapeutic efficiency of PLX4720 in an experimental model of microsatellite instable colorectal cancer
por: Rohde, Sarah, et al.
Publicado: (2017)

Selective BRAFV600E Inhibitor PLX4720, Requires TRAIL Assistance to Overcome Oncogenic PIK3CA Resistance
por: Oikonomou, Eftychia, et al.
Publicado: (2011)

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032
por: Rubinstein, Jill C, et al.
Publicado: (2010)

Tyrphostin AG1296, a platelet-derived growth factor receptor inhibitor, induces apoptosis, and reduces viability and migration of PLX4032-resistant melanoma cells
por: Li, Yanling, et al.
Publicado: (2015)

PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF(WT) melanoma cells
por: Halaban, Ruth, et al.
Publicado: (2010)

Targeting BRAF(V600E) with PLX4720 Displays Potent Antimigratory and Anti-invasive Activity in Preclinical Models of Human Thyroid Cancer
por: Nucera, Carmelo, et al.
Publicado: (2011)

The BRAF-inhibitor PLX4720 inhibits CXCL8 secretion in BRAFV600E mutated and normal thyroid cells: a further anti-cancer effect of BRAF-inhibitors
por: Coperchini, Francesca, et al.
Publicado: (2019)

RAF inhibitor PLX8394 selectively disrupts BRAF-dimers and RAS-independent BRAF mutant-driven signaling
por: Yao, Zhan, et al.
Publicado: (2018)

PLX8394, a RAF inhibitor, inhibits enterovirus 71 replication by blocking RAF/MEK/ERK signaling
por: Wu, Chengyuan, et al.
Publicado: (2023)

FOXD3 Regulates VISTA Expression in Melanoma
por: Rosenbaum, Sheera R., et al.
Publicado: (2020)

Mechanisms of resistance to RAF inhibitors in melanoma
por: Aplin, Andrew E., et al.
Publicado: (2011)

Berberine Inhibits Human Melanoma A375.S2 Cell Migration and Invasion via Affecting the FAK, uPA, and NF-κB Signaling Pathways and Inhibits PLX4032 Resistant A375.S2 Cell Migration In Vitro
por: Liu, Jia-Fang, et al.
Publicado: (2018)

Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells
por: Zhang, Honglai, et al.
Publicado: (2018)

The genesis of Zelboraf: Targeting mutant B-Raf in melanoma
por: Davis, Matthew J., et al.
Publicado: (2012)

Effects of Withdrawal Rate on the Microstructure of Directionally Solidified GH4720Li Superalloys
por: Qu, Jinglong, et al.
Publicado: (2019)

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
por: Atefi, Mohammad, et al.
Publicado: (2015)

Autophagy-Dependent Survival of Mutant B-Raf Melanoma Cells Selected for Resistance to Apoptosis Induced by Inhibitors against Oncogenic B-Raf
por: Ahn, Jun-Ho, et al.
Publicado: (2013)

FOXD1 expression-based prognostic model for uveal melanoma
por: Luo, Yang, et al.
Publicado: (2023)

FOXD3 is a tumor suppressor of colon cancer by inhibiting EGFR-Ras-Raf-MEK-ERK signal pathway
por: Li, Kun, et al.
Publicado: (2016)

Resistance to RAF inhibitors revisited
por: Hartsough, Edward, et al.
Publicado: (2013)

Mutant B-RAF Regulates a Rac-dependent Cadherin Switch in Melanoma
por: Elizabeth, Monaghan-Benson, et al.
Publicado: (2012)

NFκB-regulation of c-FLIP promotes TNFα-mediated RAF inhibitor resistance in melanoma
por: Shao, Yongping, et al.
Publicado: (2015)

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
por: Bollag, Gideon, et al.
Publicado: (2010)

ABL1/2 and DDR1 Drive MEKi Resistance in NRAS-Mutant Melanomas by Stabilizing RAF/MYC/ETS1 and Promoting RAF Homodimerization
por: Lyon, Anastasia, et al.
Publicado: (2023)

Antiproliferative Imidazo-Pyrazole-Based Hydrogel: A Promising Approach for the Development of New Treatments for PLX-Resistant Melanoma
por: Alfei, Silvana, et al.
Publicado: (2023)

Grb2 Is Regulated by Foxd3 and Has Roles in Preventing Accumulation and Aggregation of Mutant Huntingtin
por: Baksi, Shounak, et al.
Publicado: (2013)

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
por: Girotti, Maria Romina, et al.
Publicado: (2015)

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
por: Girotti, Maria Romina, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vt3629t55tlnvadaloomh9dt84